Assistant Professor, Neuropathology
University of Pennsylvania
After graduating with a degree in Mathematics from Harvard, MacLean Nasrallah, MD PhD, assistant professor of neuropathology at the Hospital of the University of Pennsylvania, taught math, physics, and community health education in Tanzania with the Peace Corps. She received her MD and PhD in neuroscience from the Perelman School of Medicine at the University of Pennsylvania, and subsequently completed residency training in Anatomic Pathology and fellowship training in Neuropathology at the Hospital of the University of Pennsylvania. Dr. Nasrallah joined the Penn Department of Pathology and Laboratory Medicine faculty in 2016.
Dr. Nasrallah’s interests include understanding the molecular pathology of brain tumors as well as understanding the relationship of tumor pathology to imaging and clinical features through machine learning work and collaboration with the larger neuro-oncology group, with the goal of refining diagnoses and treatment of brain tumors.
She is a member of the University of Pennsylvania's Center for Biomedical Image Computing and Analytics (CBICA), Center for AI and Data Science for Integrated Diagnostics (AI2D), Glioblastoma Translational Center of Excellence in the Abramson Cancer Center, and the Penn Neuro-Oncology Disease Team Leadership Council. She sits on the NCI Clinical Proteomic Tumor Analysis Consortium, the Glioma Longitudinal AnalySiS (GLASS) consortium and the Radiomics Signatures for PrecisiON Diagnostics (ReSPOND) consortium of glioblastoma. She has served as the Co-Chair of the Society for Neuro-Oncology’s (SNO) Molecular Pathology Special Interest Track (2023) and on the Professional Affairs Committee of the American Association of Neuropathologists (AANP) (2019-2023), and she received the 2023 Moore Award for Best Paper on Clinico-Pathological Correlation presented at the AANP Annual Meeting.
Disclosure(s): Kiyatec: Consultant (Terminated, August 31, 2022)
Radiomics and Radiogenomics for Brain Tumor Characterization
Monday, May 6, 2024
8:51 AM – 9:10 AM CT